文献速递骨软组织肉瘤与黑色素瘤

维持化疗改善高危横纹肌肉瘤生存:RMS 2005 III期试验

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-09-24

RMS 2005是一项多中心开放标签随机III期试验,纳入371例高危横纹肌肉瘤患者,随机分为停药组或维持化疗组(长春瑞滨+持续低剂量环磷酰胺)。

要点

  • 维持方案毒性以血液学为主,3-4级白细胞减少75%,感染31%。

核心结论

  • 在高危横纹肌肉瘤患者中,标准治疗后加用长春瑞滨联合持续低剂量环磷酰胺维持化疗似乎可改善生存。

研究设计与样本

  • RMS 2005为多中心、开放标签、随机对照III期试验,在14个国家102家医院开展。
  • 纳入6月龄至21岁高危横纹肌肉瘤患者,共371例随机1:1分配至停药组(186例)或维持化疗组(185例)。
  • 维持方案为6周期静脉长春瑞滨25 mg/m2(第1、8、15天)联合每日口服环磷酰胺25 mg/m2(第1-28天)。
  • 主要终点为意向治疗人群的无病生存,次要终点为总生存和毒性。

主要发现

  • 维持化疗组181例中136例(75%)发生3-4级白细胞减少,148例(82%)3-4级中性粒细胞减少,19例(10%)贫血,2例(1%)血小板减少,56例(31%)感染。
  • 1例(1%)发生4级非血液学毒性(神经毒性);2例治疗相关严重不良事件(抗利尿激素分泌不当综合征和严重跨阈步态伴肢体疼痛)均缓解。

关键数值与推荐

  • 高危定义包括:非转移性不完全切除的胚胎型横纹肌肉瘤位于不利部位且年龄≥10岁或肿瘤>5 cm;任何非转移性横纹肌肉瘤伴淋巴结受累;非转移性腺泡型横纹肌肉瘤无淋巴结受累。
  • 标准治疗为9周期异环磷酰胺、长春新碱、放线菌素D(±多柔比星)及手术和/或放疗。

临床怎么用

  • 对于高危横纹肌肉瘤患者,在标准治疗达到缓解后,可考虑加用6周期长春瑞滨联合持续低剂量环磷酰胺维持化疗。
  • 维持化疗期间需密切监测血液学毒性及感染,该方案毒性总体可控。

局限性

  • 研究为开放标签设计,未对研究者和患者设盲。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For more than three decades, standard treatment for rhabdomyosarcoma in Europe has included 6 months of chemotherapy. The European paediatric Soft tissue sarcoma Study Group (EpSSG) aimed to investigate whether prolonging treatment with maintenance chemotherapy would improve survival in patients with high-risk rhabdomyosarcoma. METHODS: RMS 2005 was a multicentre, open-label, randomised, controlled, phase 3 trial done at 102 hospitals in 14 countries. We included patients aged 6 months to 21 years with rhabdomyosarcoma who were considered to be at high risk of relapse: those with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring at unfavourable sites with unfavourable age (≥10 years) or tumour size (>5 cm), or both; those with any non-metastatic rhabdomyosarcoma with nodal involvement; and those with non-metastatic alveolar rhabdomyosarcoma but without nodal involvement. Patients in remission after standard treatment (nine cycles of ifosfamide, vincristine, dactinomycin with or without doxorubicin, and surgery or radiotherapy, or both) were randomly assigned (1:1) to stop treatment or continue maintenance chemotherapy (six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2, on days 1-28). Randomisation was done by use of a web-based system and was stratified (block size of four) by enrolling country and risk subgroup. Neither investigators nor patients were masked to treatment allocation. The primary outcome was disease-free survival in the intention-to-treat population. Secondary outcomes were overall survival and toxicity. This trial is registered with EudraCT, number 2005-000217-35, and ClinicalTrials.gov, number NCT00339118, and follow-up is ongoing. FINDINGS: Between April 20, 2006, and Dec 21, 2016, 371 patients were enrolled and randomly assigned to the two groups: 186 to stop treatment and 185 to receive maintenance chemotherapy. Median follow-up was 60·3 months (IQR 32·4-89·4). In the intention-to-treat population, 5-year disease-free survival was 77·6% (95% CI 70·6-83·2) with maintenance chemotherapy versus 69·8% (62·2-76·2) without maintenance chemotherapy (hazard ratio [HR] 0·68 [95% CI 0·45-1·02]; p=0·061), and 5-year overall survival was 86·5% (95% CI 80·2-90·9) with maintenance chemotherapy versus 73·7% (65·8-80·1) without (HR 0·52 [95% CI 0·32-0·86]; p=0·0097). Toxicity was manageable in patients who received maintenance chemotherapy: 136 (75%) of 181 patients had grade 3-4 leucopenia, 148 (82%) had grade 3-4 neutropenia, 19 (10%) had anaemia, two (1%) had thrombocytopenia, and 56 (31%) had an infection. One (1%) patient had a grade 4 non-haematological toxicity (neurotoxicity). Two treatment-related serious adverse events occurred: one case of inappropriate antidiuretic hormone secretion and one of a severe steppage gait with limb pain, both of which resolved. INTERPRETATION: Adding maintenance chemotherapy seems to improve survival for patients with high-risk rhabdomyosarcoma. This approach will be the new standard of care for patients with high-risk rhabdomyosarcoma in future EpSSG trials. FUNDING: Fondazione Città della Speranza, Association Léon Berard Enfant Cancéreux, Clinical Research Hospital Program (French Ministry of Health), and Cancer Research UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019. PMID: 31562043. doi:10.1016/S1470-2045(19)30617-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。